How long does dutasteride take to work for BPH?

Significant symptom improvement typically begins at 3-6 months, with continued improvement over 1-2 years. The prostate shrinks gradually as DHT is suppressed. Full benefit is seen at 12-24 months. This is a long-term medication — results require patience.

How does dutasteride affect PSA levels?

Dutasteride reduces PSA by approximately 50% over 3-6 months of use. Your doctor must interpret PSA values in this context — multiply the measured PSA by 2 to estimate what it would be without dutasteride. A rising PSA on dutasteride (even if still within 'normal' range) may indicate prostate cancer and should be investigated.

Are the sexual side effects permanent?

Most sexual side effects (reduced libido, erectile dysfunction, decreased ejaculate volume) are reversible upon stopping dutasteride. However, a small subset of patients report persistent sexual dysfunction even after discontinuation (post-finasteride/dutasteride syndrome). The FDA has updated labeling to acknowledge this risk. Discuss with your prescriber if symptoms persist after stopping.

Can women take dutasteride?

Dutasteride is FDA-approved only for men (BPH). It is used off-label by some providers for female androgenetic alopecia, but it is absolutely contraindicated in pregnancy due to risk of male fetal genital abnormalities. Postmenopausal women using it for hair loss do so only with strict contraceptive precautions (if still potentially fertile) under medical supervision.

What to Expect When Starting Dutasteride

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Introduction

Dutasteride is a 5-alpha reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the hormone responsible for prostate growth and male pattern hair loss. It is FDA-approved for benign prostatic hyperplasia (BPH). Unlike finasteride, dutasteride inhibits both type 1 and type 2 5-alpha reductase enzymes, providing more complete DHT suppression. Results require months to become apparent.

Week-by-week timeline

Week 1-4

Starting Dutasteride — No Immediate Effects

DHT levels begin to fall within 1-2 weeks, but clinical benefits take months to develop as the prostate gradually shrinks. Do not expect immediate urinary symptom improvement. Sexual side effects (reduced libido, erectile dysfunction, ejaculation changes) may appear early, even before any clinical benefit.

Month 1-2

Early Hormonal Changes

DHT is reduced by approximately 90% within 1-2 weeks of starting dutasteride. Some patients notice sexual side effects during this early period — report significant changes to your prescriber. PSA (prostate-specific antigen) levels will fall by approximately 50% over 3-6 months.

Month 3-6

Gradual Symptom Improvement

For BPH, meaningful improvements in urinary flow rate and symptom scores typically begin at 3-6 months as the prostate begins to shrink. Improvements continue for 12+ months. Prostate volume reductions of 20-25% are typical over 2 years.

Month 6-12

Continued Improvement

Urinary symptoms (frequency, urgency, weak stream, nocturia) continue to improve. Risk of acute urinary retention and need for BPH surgery are significantly reduced with long-term dutasteride therapy.

Month 12+

Long-Term Maintenance

Dutasteride is typically taken indefinitely for BPH. Stopping causes DHT to return to normal and prostate growth to resume within months. PSA should be checked annually — dutasteride halves PSA, so a 'normal' PSA on dutasteride may actually represent significant prostate cancer risk. Your doctor must account for this in interpretation.

When to call your doctor

Contact your healthcare provider if you experience:

Inability to urinate (acute urinary retention) despite being on dutasteride — seek emergency urological care
Breast tenderness or enlargement (gynecomastia) — inform your prescriber
Signs of allergic reaction: rash, facial swelling, difficulty breathing
Symptoms of depression (5-alpha reductase inhibitors are associated with mood effects in some patients)
PSA rising on dutasteride therapy (may indicate prostate cancer — requires investigation)
Sexual side effects that significantly affect quality of life — discuss with your prescriber about alternatives or dose adjustments

Tips for getting started

Dutasteride must never be handled by pregnant women or women who may become pregnant — it can cause birth defects in male fetuses. Use condoms if your female partner is pregnant or may become pregnant. Swallow the capsule whole — do not crush or chew (the medication may cause oral mucosa irritation). Donate blood only after stopping dutasteride for at least 6 months. Inform all healthcare providers you take dutasteride, as it significantly affects PSA interpretation. Women and children must not handle dutasteride capsules that are cracked or leaking.

Frequently asked questions

More about Dutasteride

Dutasteride drug guideSide effects, dosage, interactions, and more Finasteride vs DutasterideCompare these medications Dutasteride & FinasterideInteraction details

References

[Regulatory] FDA Label: Avodart (dutasteride) Soft Gelatin Capsules https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021319s018lbl.pdf Accessed 2026-03-01.
[Regulatory] NIH MedlinePlus: Dutasteride https://medlineplus.gov/druginfo/meds/a603001.html Accessed 2026-03-01.
[Regulatory] AUA BPH Guidelines: Medical Therapy https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(bph)-guideline Accessed 2026-03-01.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: March 1, 2026